Eravacycline: The Tetracyclines Strike Back
| Autor: | Monica V Mahoney, Maria Heaney, Jason C. Gallagher |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Methicillin-Resistant Staphylococcus aureus medicine.medical_specialty medicine.drug_class Antibiotics Carbapenem-resistant enterobacteriaceae medicine.disease_cause Meropenem 03 medical and health sciences chemistry.chemical_compound Internal medicine medicine Humans Pharmacology (medical) Vancomycin-resistant Enterococcus 030304 developmental biology 0303 health sciences 030306 microbiology business.industry Eravacycline Methicillin-resistant Staphylococcus aureus chemistry Tolerability Tetracyclines business Ertapenem medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 53:1124-1135 |
| ISSN: | 1542-6270 1060-0280 |
| Popis: | Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of eravacycline, a novel fluorocycline antibiotic from the tetracycline family. Data Sources: A PubMed search was conducted for data between 1946 and March 2019 using MeSH terms eravacycline and TP-434. An internet search was conducted for unpublished clinical research. Study Selection and Data Extraction: The literature search was limited to English-language studies that described clinical efficacy, safety, and pharmacokinetics in humans and animals. Abstracts featuring prepublished data were also evaluated for inclusion. Data Synthesis: Eravacycline has in vitro activity against multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus, extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacteriaceae, and Acinetobacter. It was approved for the treatment of complicated intra-abdominal infections (cIAIs) in adults following favorable results of 2 phase III trials, IGNITE 1 and IGNITE 4, compared with ertapenem and meropenem, respectively. The most common adverse drug events associated with eravacycline were infusion site reactions (7.7%), nausea (6.5%), vomiting (3.7%), and diarrhea (2.3%). Relevance to Patient Care and Clinical Practice: Eravacycline will likely be most useful for resistant infections when lack of tolerability, resistant phenotypes, or allergies prevent the use of β-lactams. Conclusions: Eravacycline is a new tetracycline antibiotic with a broad spectrum of activity that has demonstrated efficacy in the treatment of cIAIs. Although it has activity against multidrug-resistant organisms, data are limited for other indications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|